Navigation Links
Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
Date:12/8/2008

y expected with interferon therapy. The incidence of discontinuations due to adverse events was 5.5% (17/310) in the treatment group originally randomized to receive 1200-mcg albinterferon alfa-2b every two weeks, vs. 3.6% (11/309) in the peginterferon alfa-2a treatment group.

About Albinterferon Alfa-2b (Albuferon)

Albinterferon alfa-2b is a novel, longer-acting form of interferon alfa that was created using the proprietary HGS albumin-fusion technology. Human albumin is the most prevalent naturally occurring blood protein in the human circulatory system, persisting in circulation in the body for approximately 19 days. Research has shown that genetic fusion of therapeutic proteins to human albumin decreases clearance and prolongs the half-life of the therapeutic proteins. Albuferon results from the genetic fusion of human albumin and interferon alfa.

Albuferon is being developed by HGS and Novartis for the treatment of chronic hepatitis C under an exclusive worldwide co-development and commercialization agreement entered into in June 2006. HGS and Novartis will co-commercialize Albuferon in the United States and will share clinical development costs, U.S. commercialization costs and U.S. profits equally. Novartis will be responsible for commercialization in the rest of the world and will pay HGS a royalty on those sales. Clinical development, commercial milestone and other payments to HGS could total as much as $507.5 million, including $132.5 million received to date.

About Hepatitis C

Hepatitis C is an inflammation of the liver caused by the hepatitis C virus. It is estimated that as many as 170 million people worldwide are infected with hepatitis C virus. This includes nearly four million people in the United States. When detectable levels of HCV persist in the blood for at least six months, a person is diagnosed wit
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015 According to a ... Cell Culture: Asia to Witness ... the global 3D cell culture market was valued at US$ 586.1 ... a CAGR of 29.1% to account for US$ 2,717.6 ... TOC:  http://www.persistencemarketresearch.com/market-research/3d-cell-cultures-market.asp 3D cell culture refers ...
(Date:7/31/2015)... 31, 2015 In today,s fast changing ... them drive positive health outcomes, improve profitability and ... patient care in their communities. At ThoughtSpot 2015, ... conference, AmerisourceBergen announced a new set of innovative ... Organization and help independent pharmacies endure the industry,s ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... and quantification of partially hydrolyzed gluten in foods, has been accepted by AOAC ... method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based ...
(Date:7/30/2015)... , July 30, 2015   GenoSpace ... for the interpretation and analysis of genomic and ... Fischer has joined the company as Vice ... - http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace ... to integrate, interpret, analyze and explore complex sets ...
Breaking Biology Technology:Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2
... Stem Cell Treatments -- SHENZHEN, China, Sept. 2 /PRNewswire-Asia/ -- ... ... ... first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
... everything from antibacterial socks to medical imaging to ... health and safety risks of these particles also ... and Technology (NIST) have developed a simple process ... certain physical and chemical properties that affect how ...
... ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS... -- YOKOHAMA, Japan, September 1, ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so ...
Cached Biology Technology:New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments 2New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments 3New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments 4New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments 5New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments 6New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments 7New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments 8The perfect nanocube: Precise control of size, shape and composition 2ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 2ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 3ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 4ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 5ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 6
(Date:7/27/2015)... 27, 2015   Zynx Health ™, the ... improvement solutions, today announced that its ZynxCarebook ... on Android smartphones and tablets. With this expansion, ... can use ZynxCarebook to securely exchange messages and ... care transitions to other care settings, and improve ...
(Date:7/21/2015)... Passwords have proven futile for securing ... U.S. Office of Personnel Management breach. Biometric authentication ... but developers and end-users are concerned about how ... Biometrics-as-a-Service provider HYPR Corp. announced today the general ... party integration. A video overview ...
(Date:7/9/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/98rrmr/biometrics_for ... "Biometrics for Banking; Market & Technology Analysis, Adoption ... offering. The adoption for banking purposes ... the forecast is that by 2020 it will ... in delivering biometric systems to the banking industry. ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... Denizens of oceans, lakes and even wet ... intricately patterned, glass-like shells. Curiously, these tiny phytoplankton could ... Diatoms build their hard cell walls by laying down ... key material of the semiconductor industrysilicon. If we can ...
... stem cells from mice, UT Southwestern Medical Center researchers ... importantly, functioning muscle cells in mice afflicted with ... study represents the first time transplanted embryonic stem cells ... in a model of muscular dystrophy. The researchers ...
... in French . , A study led ... between individuals at the DNA level can lead to ... in turn, are responsible for the vast array of ... of the Genome Regulators in Disease (GRID) Project funded ...
Cached Biology News:In diatom, scientists find genes that may level engineering hurdle 2Stem-cell transplantation improves muscles in MD animal model, UT Southwestern researchers report 2Stem-cell transplantation improves muscles in MD animal model, UT Southwestern researchers report 3Tiny genetic differences have huge consequences: McGill researchers 2
Use the DUALmembrane kit 3 to carry out DUALmembrane interaction analysis and cDNA library screening to characterize interactions between integral membrane proteins and to identify novel interaction ...
... Waterproof, moisture-proof film prevents sample evaporation, ... folded repeatedly and twisted around sharp ... 21C (70F), wrapping film increases approximately ... film only partially returns to original ...
PlusOne EDTA, disodium salt, 100 g. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Buffers....
...
Biology Products: